Morgan Stanley’s BioXcel Therapeutics BTAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$2.86K Sell
1,580
-186
-11% -$337 ﹤0.01% 7155
2025
Q1
$3.59K Buy
1,766
+154
+10% +$313 ﹤0.01% 7071
2024
Q4
$9.65K Sell
1,612
-926
-36% -$5.54K ﹤0.01% 6817
2024
Q3
$24.8K Sell
2,538
-4,747
-65% -$46.3K ﹤0.01% 6441
2024
Q2
$149K Sell
7,285
-6,609
-48% -$135K ﹤0.01% 5799
2024
Q1
$627K Sell
13,894
-10,075
-42% -$455K ﹤0.01% 5208
2023
Q4
$1.13M Buy
23,969
+11,264
+89% +$532K ﹤0.01% 5239
2023
Q3
$514K Buy
12,705
+6,901
+119% +$279K ﹤0.01% 5158
2023
Q2
$618K Sell
5,804
-2,327
-29% -$248K ﹤0.01% 5110
2023
Q1
$2.43M Buy
8,131
+319
+4% +$95.2K ﹤0.01% 4335
2022
Q4
$2.68M Sell
7,812
-8,109
-51% -$2.79M ﹤0.01% 4266
2022
Q3
$3.01M Buy
15,921
+1,743
+12% +$330K ﹤0.01% 4111
2022
Q2
$2.99M Buy
14,178
+989
+7% +$209K ﹤0.01% 4213
2022
Q1
$4.41M Sell
13,189
-1,481
-10% -$495K ﹤0.01% 3817
2021
Q4
$4.77M Buy
14,670
+7,124
+94% +$2.32M ﹤0.01% 3770
2021
Q3
$3.66M Buy
7,546
+92
+1% +$44.7K ﹤0.01% 4046
2021
Q2
$3.47M Buy
7,454
+5,937
+391% +$2.76M ﹤0.01% 4156
2021
Q1
$1.05M Buy
1,517
+114
+8% +$78.7K ﹤0.01% 4705
2020
Q4
$1.04M Buy
1,403
+283
+25% +$209K ﹤0.01% 4649
2020
Q3
$777K Buy
1,120
+663
+145% +$460K ﹤0.01% 4383
2020
Q2
$388K Buy
457
+178
+64% +$151K ﹤0.01% 4726
2020
Q1
$100K Sell
279
-359
-56% -$129K ﹤0.01% 5185
2019
Q4
$149K Buy
638
+468
+275% +$109K ﹤0.01% 5519
2019
Q3
$19K Buy
170
+167
+5,567% +$18.7K ﹤0.01% 6027
2019
Q2
$0 Sell
3
-151
-98% ﹤0.01% 6647
2019
Q1
$24K Sell
154
-105
-41% -$16.4K ﹤0.01% 5951
2018
Q4
$16K Sell
259
-67
-21% -$4.14K ﹤0.01% 6057
2018
Q3
$41K Buy
326
+249
+323% +$31.3K ﹤0.01% 5925
2018
Q2
$11K Sell
77
-106
-58% -$15.1K ﹤0.01% 6278
2018
Q1
$30K Buy
+183
New +$30K ﹤0.01% 6024